SJEPD032244_D1.RNA-Seq
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- age_years
- 12.42
- e1_e2
- E2
- umap1_2d
- -5.280759457
- umap2_2d
- 1.114542485
- umap1_3d
- -0.699545946
- umap2_3d
- 3.129076225
- umap3_3d
- 0.14198796
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.530
- TNFA_SIGNALING_VIA_NFKB+0.520
- ANGIOGENESIS+0.450
- IL6_JAK_STAT3_SIGNALING+0.450
- INTERFERON_GAMMA_RESPONSE+0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- INFLAMMATORY_RESPONSE+0.440
- IL2_STAT5_SIGNALING+0.430
- TGF_BETA_SIGNALING+0.420
- COMPLEMENT+0.400
Top 10 suppressed
- E2F_TARGETS-0.450
- G2M_CHECKPOINT-0.430
- DNA_REPAIR-0.330
- MITOTIC_SPINDLE-0.250
- WNT_BETA_CATENIN_SIGNALING-0.250
- FATTY_ACID_METABOLISM-0.230
- CHOLESTEROL_HOMEOSTASIS-0.210
- PEROXISOME-0.180
- MYC_TARGETS_V1-0.150
- GLYCOLYSIS-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR13780252 | — | cohortMD2 | 0.881 |
| 2 | SRR22247245 | — | cohortMD2 | 0.877 |
| 3 | ERR2598287 | fetal | fetal | 0.874 |
| 4 | TCGA-05-4417-01A-22R-1858-07 | — | cohortA3 | 0.866 |
| 5 | SRR1797302 | — | cohortMD2 | 0.859 |
| 6 | SRR8526727 | — | cohortMD2 | 0.853 |
| 7 | MDT-AP-2658 | Med | Medulloblastoma | 0.853 |
| 8 | MDT-AP-2651 | Med | Medulloblastoma | 0.852 |
| 9 | 110682 | EPN | Supratentorial EPN | 0.850 |
| 10 | SRR601755 | GTEX | — | 0.849 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.520 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.430 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.310 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |